Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Abiraterone Acetate
100%
Single-center Experience
100%
Abiraterone
100%
Patient Management
25%
Radiographic Progression
25%
Overall Survival
25%
Consecutive Patients
25%
Phase II Trial
25%
Castration-resistant Prostate Cancer
25%
Prostate-specific Antigen Response
25%
Routine Management
12%
Clinical Progression
12%
Androgen Synthesis
12%
Clinical Experience
12%
Single-center Retrospective Study
12%
Trial Outcomes
12%
Phase II Study
12%
Clinical Trials
12%
Prednisone
12%
Patient Selection
12%
Continuous Stimulation
12%
Enzyme System
12%
Clinical Practice
12%
Twice Daily
12%
Post-chemotherapy
12%
Prostate-specific Antigen
12%
Androgen Receptor
12%
Denmark
12%
Potent Inhibitor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Abiraterone Acetate
100%
Abiraterone
100%
Prostate Specific Antigen
37%
Overall Survival
25%
Prednisone
12%
Taxane
12%
Weakness
12%
Retrospective Study
12%
Clinical Trial
12%
Androgen Receptor
12%
Androgen
12%
Chemotherapy
12%
Enzyme
12%
Medicine and Dentistry
Abiraterone
100%
Abiraterone Acetate
100%
Antigen Response
25%
Nursing and Health Professions
Abiraterone
100%
Abiraterone Acetate
100%
Enzyme
12%
Prednisone
12%